Patients suffering from OSA present increased levels of oxidative stress, systemic inflammation and hypoxia-inducible factors (HIF) including their downstream gene products such as vascular endothelial growth factor (VEGF), a regulator and promoter of angiogenesis [3,4]. The gene discussed is VEGFA; the disease is obstructive sleep apnea syndrome.